Oral epithelial stem cells-Implications in normal development and cancer metastasis

Experimental Cell Research

Volumn 325, Issue 2, 2014, Pages 111-129

  Papagerakis, Silvana ^a,b   Pannone, Giuseppe ^c   Zheng, Li ^a,b   About, Imad ^d   Taqi, Nawar ^b   Nguyen, Nghia P T ^a   Matossian, Margarite ^a   McAlpin, Blake ^a,b   Santoro, Angela ^c   McHugh, Jonathan ^a   Prince, Mark E ^a   Papagerakis, Petros ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^c UNIVERSITY OF FOGGIA   (Italy)

^d AIX MARSEILLE UNIVERSITÉ   (France)

Author keywords

Cancer stem cells; Epithelial stem cells; Invasion; Metastasis; Oral mucosa; Oral squamous cell carcinoma

Indexed keywords

SURVIVIN;

CANCER STEM CELL; CARCINOGENESIS; CELL PROLIFERATION; DNA METHYLATION; HUMAN; METASTASIS; MOUTH CAVITY; MOUTH MUCOSA; MOUTH SQUAMOUS CELL CARCINOMA; ORAL EPITHELIAL STEM CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVIEW; SIDE POPULATION CELL; SIGNAL TRANSDUCTION; STEM CELL; STEM CELL RESEARCH;

CANCER STEM CELLS; EPITHELIAL STEM CELLS; INVASION; METASTASIS; ORAL MUCOSA; ORAL SQUAMOUS CELL CARCINOMA;

ANIMALS; CARCINOMA, SQUAMOUS CELL; EPITHELIUM; HUMANS; MOUTH MUCOSA; MOUTH NEOPLASMS; STEM CELLS;

EID: 84903604684     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2014.04.021     Document Type: Review

References (225)

1. Iglesias-Bartolome R., Callejas-Valera J.L., Gutkind J.S. Control of the epithelial stem cell epigenome: the shaping of epithelial stem cell identity. Curr. Opin. Cell Biol. 2013, 25:162-169.
2. Sinha N., Mukhopadhyay S., Das D.N., Panda P.K., Bhutia S.K. Relevance of cancer initiating/stem cells in carcinogenesis and therapy resistance in oral cancer. Oral Oncol. 2013, 49:854-862.
3. Winning T.A., Townsend G.C. Oral mucosal embryology and histology. Clin. Dermatol. 2000, 18:499-511.
4. Rothova M., Thompson H., Lickert H., Tucker A.S. Lineage tracing of the endoderm during oral development. Dev. Dyn. 2012, 241:1183-1191.
5. Jones K.B., Klein O.D. Oral epithelial stem cells in tissue maintenance and disease: the first steps in a long journey. Int. J. Oral Sci. 2013, 5:121-129.
6. Collins L.M., Dawes C. The surface area of the adult human mouth and thickness of the salivary film covering the teeth and oral mucosa. J. Dent. Res. 1987, 66:1300-1302.
7. Nguyen L.V., Vanner R., Dirks P., Eaves C.J. Cancer stem cells: an evolving concept. Nat. Rev. Cancer 2012, 12:133-143.
8. Richard V., Pillai M.R. The stem cell code in oral epithelial tumorigenesis: the cancer stem cell shift hypothesis. Biochim. Biophys. Acta 2010, 1806:146-162.
9. Abdulmajeed A.A., Dalley A.J., Farah C.S. Putative cancer stem cell marker expression in oral epithelial dysplasia and squamous cell carcinoma. J. Oral Pathol. Med. Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 2013.
10. Squier C.A., Kremer M.J. Biology of oral mucosa and esophagus. J. Nat. Cancer Inst. Monogr. 2001, 7-15.
11. Squier C.A., Johnson N.W., Hopps R.M. Human Oral Mucosa: Development, Structure and Function 1976, Blackwell Scientific, Oxford.
12. Wu T., Xiong X., Zhang W. Morphogenesis of rete ridges in human oral mucosa: a pioneering morphological and immunohistochemical study. Cell Tissues Organs 2013, 197:239-248.
13. R. Lanza, Essential of Stem Cell Bilogy. second ed. In: (Eds.) R. Lanza, J. Gearhart, B. Hogan, D. Melton, R. Pedersen, E.D. Thomas, J. Thomson, Sir I. Wilmut, Elsevier Inc. Academic Press. http://isbn:%20978-0-12-374729-7.
14. Jones P.H., Simons B.D., Watt F.M. Sic transit gloria: farewell to the epidermal transit amplifying cells?. Cell Stem Cell 2007, 1:371-381.
15. Li Y., Laterra J. Cancer stem cells: distinct entities or dynamically regulated phenotypes?. Cancer Res. 2012, 72:576-580.
16. Bjarnason G.A., Jordan R.C., Sothern R.B. Circadian variation in the expression of cell-cycle proteins in human oral epithelium. Am. J. Pathol. 1999, 154:613-622.
17. Thomson P.J., Potten C.S., Appleton D.R. Mapping dynamic epithelial cell proliferative activity within the oral cavity of man: a new insight into carcinogenesis?. Br. J. Oral Maxillofacial Surg. 1999, 37:377-383.
18. Hume W.J., Potten C.S. The ordered columnar structure of mouse filiform papillae. J. Cell Sci. 1976, 22:149-160.
19. Hume W.J., Potten C.S. Proliferative units in startified squamous epithelium. Clin. Exp. Dermatol. 1983, 8:95-106.
20. Kellett M., Hume W.J., Potten C.S. A topographical study of the circadian rhythm in labelling index of mouse gingival and floor-of-mouth epithelium, including changes in labelling activity with individual cell position on the epithelial ridges. Arch. Oral Biol. 1989, 34:321-328.
21. Janich P., Pascual G., Merlos-Suárez A., Batlle E., Ripperger J., Albrecht U., Cheng H.Y., Obrietan K., Di Croce L., Benitah S.A. The circadian molecular clock creates epidermal stem cell heterogeneity. Nature 2011, 480:209-214.
22. Zheng L., Papagerakis S., Schnell S.D., Hoogerwerf W.A., Papagerakis P. Expression of clock proteins in developing tooth. Gene Expression Patterns: GEP 2011, 11:202-206.
23. Grimm M., Renz C., Munz A., Hoefert S., Krimmel M., Reinert S. Co-expression of CD44+/RANKL+ tumor cells in the carcinogenesis of oral squamous cell carcinoma. Odontology 2013.
24. Abhold E.L., Kiang A., Rahimy E., Kuo S.Z., Wang-Rodriguez J., Lopez J.P., Blair K.J., Yu M.A., Haas M., Brumund K.T., Altuna X., Patel A., Weisman R.A., Ongkeko W.M. EGFR kinase promotes acquisition of stem cell-like properties: a potential therapeutic target in head and neck squamous cell carcinoma stem cells. PLoS One 2012, 7:e32459.
25. Du J., Chen G.G., et al. The nuclear localization of NFkappaB and p53 is positively correlated with HPV16 E7 level in laryngeal squamous cell carcinoma. J. Histochem. Cytochem. 2003, 51:533-539.
26. Nickoloff B.J., Osborne B.A., et al. Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene 2003, 22:6598-6608.
27. Al-Hajj M., Clarke M.F. Self-renewal and solid tumor stem cells. Oncogene 2004, 23:7274-7282.
28. Karhadkar S.S, Bova G.S., et al. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 2004, 431:707-712.
29. Dolled-Filhart M., McCabe A., et al. Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res. 2006, 66:5487-5494.
30. Klaus A., Birchmeier Wnt W. signalling and its impact on development and cancer. Nat. Rev. Cancer 2008, 8:387-398.
31. Prise K.M., Saran A. Concise review: stem cell effects in radiation risk. Stem Cells 2011, 29:1315-1321.
32. Carvalho A.L., Chuang A., et al. Deleted in colorectal cancer is a putative conditional tumor-suppressor gene inactivated by promoter hypermethylation in head and neck squamous cell carcinoma. Cancer Res. 2006, 66:9401-9407.
33. Tan H.K, Saulnier P., et al. Quantitative methylation analyses of resection margins predict local recurrences and disease-specific deaths in patients with head and neck squamous cell carcinomas. Br. J. Cancer 2008, 99:357-363.
34. Sun W., Zaboli D., et al. Detection of TIMP3 promoter hypermethylation in salivary rinse as an independent predictor of local recurrence-free survival in head and neck cancer. Clin. Cancer Res. 2012, 18:1082-1091.
35. Colacino J.A., Dolinoy D.C., et al. Comprehensive analysis of DNA methylation in head and neck squamous cell carcinoma indicates differences by survival and clinicopathologic characteristics. PLoS One 2013, 8:e54742.
36. Agrawal N., Frederick M.J., et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011, 333:1154-1157.
37. Stransky N., Egloff A.M., et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011, 333:1157-1160.
38. Sartor M.A., Dolinoy D.C., et al. Genome-wide methylation and expression differences in HPV(+) and HPV(-) squamous cell carcinoma cell lines are consistent with divergent mechanisms of carcinogenesis. Epigenetics 2011, 6:777-787.
39. Colacino J.A., Arthur A.E., et al. Pretreatment dietary intake is associated with tumor suppressor DNA methylation in head and neck squamous cell carcinomas. Epigenetics 2012, 7:883-891.
40. Arbes S.J., Olshan A.F., Caplan D.J., Schoenbach V.J., Slade G.D., Symons M.J. Factors contributing to the poorer survival of black Americans diagnosed with oral cancer (United States). Cancer Causes Control 1999, 10:513-523.
41. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA: Cancer J. Clin. 2011, 61:69-90.
42. Canto M.T., Drury T.F., Horowitz A.M. Oral cancer examinations among U.S. Hispanics in 1998. J. Cancer Educ. 2003, 18:48-52.
43. Horowitz A.M., Moon H.S., Goodman H.S., Yellowitz J.A. Maryland adults' knowledge of oral cancer and having oral cancer examinations. J. Public Health Dent. 1998, 58:281-287.
44. Eliassen A.M., Hauff S.J., Tang A.L., Thomas D.H., McHugh J.B., Walline H.M., Stoerker J., Maxwell J.H., Worden F.P., Eisbruch A., Czerwinski M.J., Papagerakis S.M., Chepeha D.B., Bradford C.R., Hanauer D.A., Carey T.E., Prince M.E. Head and neck squamous cell carcinoma in pregnant women. Head Neck 2013, 35:335-342.
45. Cruz G.D., Le Geros R.Z., et al. Oral cancer knowledge, risk factors and characteristics of subjects in a large oral cancer screening program. J. Am. Dent. Assoc. 2002, 133:1064-1071.
46. Hashibe M., Brennan P., et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the international head and neck cancer epidemiology consortium. Cancer Epidemiol. Biomarkers Prev. 2009, 18:541-550.
47. Ahn J., Chen C.Y., et al. Oral microbiome and oral and gastrointestinal cancer risk. Cancer Causes Control 2012, 23:399-404.
48. Hausen H. Infections Causing Human Cancer 2006, Wiley-VCH Verlag, Weinheim, Germany.
49. Pannone G., Santoro A., et al. The role of human papillomavirus in the pathogenesis of head & neck squamous cell carcinoma: an overview. Infect. Agent Cancer 2011, 6:4.
50. Vidal L., Gillison M.L. Human papillomavirus in HNSCC: recognition of a distinct disease type. Hematol. Oncol. Clin. North Am. 2008, 22:1125-1142.
51. Chenevert J., Seethala R.R., et al. Squamous cell carcinoma metastatic to neck from an unknown primary: the potential impact of modern pathologic evaluation on perceived incidence of human papillomavirus-positive oropharyngeal carcinoma prior to 1970. Laryngoscope 2012, 122:793-796.
52. Applebaum K.M., Furniss C.S., et al. Lack of association of alcohol and tobacco with HPV16-associated head and neck cancer. J. Nat. Cancer Inst. 2007, 99:1801-1810.
53. Gillison M.L., D'Souza G., et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J. Nat. Cancer Inst. 2008, 100:407-420.
54. Arthur A.E., Duffy S.A., et al. Higher micronutrient intake is associated with human papillomavirus-positive head and neck cancer: a case-only analysis. Nutr. Cancer 2011, 63:734-742.
55. Wansom D.E., Light E., et al. Infiltrating lymphocytes and human papillomavirus-16-associated oropharyngeal cancer. Laryngoscope 2012, 122:121-127.
56. Fakhry C., Westra W.H., et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J. Nat. Cancer Inst. 2008, 100:261-269.
57. Maxwell J.H., Kumar B., et al. Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin. Cancer Res. 2010, 16:1226-1235.
58. Worden F.P., Kumar B., et al. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J. Clin. Oncol. 2008, 26:3138-3146.
59. Kumar B., Cordell K.G., et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J. Clin. Oncol. 2008, 26:3128-3137.
60. Shah J., Johnson N., Batsakis J. Oral Cancer 2003, Martin Dunitz Press, London.
61. Myers J. Oral Cancer Metastasis 2010, Soringer Sciences, LLC, New York, NY.
62. de Bree R., Haigentz M., Silver C.E., Paccagnella D., Hamoir M., Hartl D.M., Machiels J.P., Paleri V., Rinaldo A., Shaha A.R., Takes R.P., Leemans C.R., Ferlito A. Distant metastases from head and neck squamous cell carcinoma. Part II. Diagnosis. Oral Oncol. 2012, 48:780-786.
63. Garavello W., Ciardo A., Spreafico R., Gaini R.M. Risk factors for distant metastases in head and neck squamous cell carcinoma. Arch. Otolaryngol.-Head Neck Surg. 2006, 132:762-766.
64. Liao C.T., Wang H.M., Hsieh L.L., Chang J.T., Ng S.H., Hsueh C., Lee L.Y., Lin C.H., Chen I.H., Kang C.J., Huang S.F., Yen T.C. Higher distant failure in young age tongue cancer patients. Oral Oncol. 2006, 42:718-725.
65. Haigentz M., Hartl D.M., Silver C.E., Langendijk J.A., Strojan P., Paleri V., de Bree R., Machiels J.P., Hamoir M., Rinaldo A., Paccagnella D., Shaha A.R., Takes R.P., Ferlito A. Distant metastases from head and neck squamous cell carcinoma. Part III. Treatment. Oral Oncol. 2012, 48:787-793.
66. Chinn S.B., Darr O.A., Peters R.D., Prince M.E. The role of head and neck squamous cell carcinoma cancer stem cells in tumorigenesis, metastasis, and treatment failure. Front. Endocrinol. 2012, 3:90.
67. Desai P.C., Jaglal M.V., Gopal P., Ghim S.J., Miller D.M., Farghaly H., Jenson A.B. Human papillomavirus in metastatic squamous carcinoma from unknown primaries in the head and neck: a retrospective 7 year study. Exp. Mol. Pathol. 2009, 87:94-98.
68. Albers A.E., Chen C., Koberle B., Qian X., Klussmann J.P., Wollenberg B., Kaufmann A.M. Stem cells in squamous head and neck cancer. Crit. Rev. Oncol./Hematol. 2012, 81:224-240.
69. Ostrand-Rosenberg S. Immune surveillance: a balance between protumor and antitumor immunity. Curr. Opin. Genet. Dev. 2008, 18:11-18.
70. Rapidis A.D., Wolf G.T. Immunotherapy of head and neck cancer: current and future considerations. J. Oncol. 2009, 2009:346345.
71. Whiteside T.L. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008, 27:5904-5912.
72. Accomando W.P., Wiencke J.K., Houseman E.A., Butler R.A., Zheng S., Nelson H.H., Kelsey K.T. Decreased NK cells in patients with head and neck cancer determined in archival DNA. Clin. Cancer Res. 2012, 18:6147-6154.
73. Duray A., Demoulin S., Hubert P., Delvenne P., Saussez S. Immune suppression in head and neck cancers: a review. Clin. Dev. Immunol. 2010, 2010:701657.
74. Kuss I., Hathaway B., Ferris R.L., Gooding W., Whiteside T.L. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin. Cancer Res. 2004, 10:3755-3762.
75. Kuss I., Hathaway B., Ferris R.L., Gooding W., Whiteside T.L. Imbalance in absolute counts of T lymphocyte subsets in patients with head and neck cancer and its relation to disease. Adv. Otorhinolaryngol. 2005, 62:161-172.
76. Wulff S., Pries R., Borngen K., Trenkle T., Wollenberg B. Decreased levels of circulating regulatory NK cells in patients with head and neck cancer throughout all tumor stages. Anticancer Res. 2009, 29:3053-3057.
77. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., Minden M., Paterson B., Caligiuri M.A., Dick J.E. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
78. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Nat. Acad. Sci. U.S.A. 2003, 100:3983-3988.
79. Ginestier C., Hur M.H., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., Jacquemier J., Viens P., Kleer C.G., Liu S., Schott A., Hayes D., Birnbaum D., Wicha M.S., Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567.
80. Hermann P.C., Huber S.L., Herrler T., Aicher A., Ellwart J.W., Guba M., Bruns C.J., Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1:313-323.
81. Yin S., Li J., Hu C., Chen X., Yao M., Yan M., Jiang G., Ge C., Xie H., Wan D., Yang S., Zheng S., Gu J. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int. J. Cancer 2007, 120:1444-1450.
82. Li C., Wu J.-J., Hynes M., Dosch J., Sarkar B., Welling T.H., Pasca di Magliano M., Simeone D.M. c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology 2011, 141:2218-2227.
83. Beier D., Hau P., Proescholdt M., Lohmeier A., Wischhusen J., Oefner P.J., Aigner L., Brawanski A., Bogdahn U., Beier C.P. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 2007, 67:4010-4015.
84. Dalerba P., Dylla S.J., Park I.-K., Liu R., Wang X., Cho R.W., Hoey T., Gurney A., Huang E.H., Simeone D.M., Shelton A.A., Parmiani G., Castelli C., Clarke M.F. Phenotypic characterization of human colorectal cancer stem cells. Proc. Nat. Acad. Sci. U.S.A. 2007, 104:10158-10163.
85. Ma S., Chan K.W., Lee T.K.-W., Tang K.H., Wo J.Y.-H., Zheng B.-J., Guan X.-Y. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol. Cancer Res. 2008, 6:1146-1153.
86. Todaro M., Alea M.P., Di Stefano A.B., Cammareri P., Vermeulen L., Iovino F., Tripodo C., Russo A., Gulotta G., Medema J.P., Stassi G. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007, 1:389-402.
87. Yang Z.F., Ngai P., Ho D.W., Yu W.C., Ng M.N.P., Lau C.K., Li M.L.Y., Tam K.H., Lam C.T., Poon R.T.P., Fan S.T. Identification of local and circulating cancer stem cells in human liver cancer. Hepatology (Baltimore, Md.) 2008, 47:919-928.
88. Huang E.H., Hynes M.J., Zhang T., Ginestier C., Dontu G., Appelman H., Fields J.Z., Wicha M.S., Boman B.M. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res. 2009, 69:3382-3389.
89. Chen Y.-C., Chen Y.-W., Hsu H.-S., Tseng L.-M., Huang P.-I., Lu K.-H., Chen D.-T., Tai L.-K., Yung M.-C., Chang S.-C., Ku H.-H., Chiou S.-H., Lo W.-L. Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem. Biophys. Res. Commun. 2009, 385:307-313.
90. Cheung P.F.Y., Cheng C.K.C., Wong N.C.L., Ho J.C.Y., Yip C.W., Lui V.C.H., Cheung A.N.Y., Fan S.T., Cheung S.T. Granulin-epithelin precursor is an oncofetal protein defining hepatic cancer stem cells. PLoS One 2011, 6.
91. Prince M.E., Sivanandan R., Kaczorowski A., Wolf G.T., Kaplan M.J., Dalerba P., Weissman I.L., Clarke M.F., Ailles L.E. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc. Nat. Acad. Sci. U.S.A. 2007, 104:973-978.
92. Clay M.R., Tabor M., Owen J.H., Carey T.E., Bradford C.R., Wolf G.T., Wicha M.S., Prince M.E. Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck 2010, 32:1195-1201.
93. Krishnamurthy S., Dong Z., Vodopyanov D., Imai A., Helman J.I., Prince M.E., Wicha M.S., Nor J.E. Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells. Cancer Res. 2010, 70:9969-9978.
94. Czerwinski M.J., Desiderio V., Shkeir O., Papagerakis P., Lapadatescu M.C., Owen J.H., Athanassiou-Papaefthymiou M., Zheng L., Papaccio G., Prince M.E., Papagerakis S. In vitro evaluation of sialyl Lewis X relationship with head and neck cancer stem cells. Otolaryngol. Head Neck Surg. 2013, 149:97-9104.
95. Krishnamurthy S., Nor J.E. Orosphere assay: a method for propagation of head and neck cancer stem cells. Head Neck 2013, 35:1015-1021.
96. Rodda D.J., Chew J.-L., Lim L.-H., Loh Y.-H., Wang B., Ng H.-H., Robson P. Transcriptional regulation of nanog by OCT4 and SOX2. J. Biol. Chem. 2005, 280:24731-24737.
97. Yang J., Mani S.A., Weinberg R.A. Exploring a new twist on tumor metastasis. Cancer Res. 2006, 66:4549-4552.
98. Chiou S.-H., Yu C.-C., Huang C.-Y., Lin S.-C., Liu C.-J., Tsai T.-H., Chou S.-H., Chien C.-S., Ku H.-H., Lo J.-F. Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin. Cancer ResearchAn Official Journal of the American Association for Cancer Research 2008, 14:4085-4095.
99. Wei X.D., Zhou L., Cheng L., Tian J., Jiang J.J., Maccallum J. In vivo investigation of CD133 as a putative marker of cancer stem cells in Hep-2 cell line. Head Neck 2009, 31:94-9101.
100. John M.A., Dohadwala M., Luo J., Wang G., Lee G., Shih H., Heinrich E., Krysan K., Walser T., Hazra S., Zhu L., Lai C., Abemayor E., Fishbein M., Elashoff D.A., Sharma S., Dubinett S.M. Proinflammatory mediators upregulate snail in head and neck squamous cell carcinoma. Clin. Cancer Research An Official Journal of the American Association for Cancer Research 2009, 15:6018-6027.
101. Vered M., Dayan D., Yahalom R., Dobriyan A., Barshack I., Bello I.O., Kantola S., Salo T. Cancer-associated fibroblasts and epithelial-mesenchymal transition in metastatic oral tongue squamous cell carcinoma. Int. J. Cancer 2010, 127:1356-1362.
102. Goodison S., Urquidi V., Tarin D. CD44 cell adhesion molecules. Mol.r Pathol.: MP 1999, 52:189-196.
103. Naor D., Wallach-Dayan S.B., Zahalka M.A., Sionov R.V. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin. Cancer Biol. 2008, 18:260-267.
104. Wang S.J., Wong G., de Heer A.M., Xia W., Bourguignon L.Y. CD44 variant isoforms in head and neck squamous cell carcinoma progression. Laryngoscope 2009, 119:1518-1530.
105. de Jong M.C., Pramana J., van der Wal J.E., Lacko M., Peutz-Kootstra C.J., de Jong J.M., Takes R.P., Kaanders J.H., van der Laan B.F., Wachters J., Jansen J.C., Rasch C.R., van Velthuysen M.-L.F., Grenman R., Hoebers F.J., Schuuring E., van den Brekel M.W., Begg A.C. CD44 expression predicts local recurrence after radiotherapy in larynx cancer. Clin. Cancer Res. An Official Journal of the American Association for Cancer Research 2010, 16:5329-5338.
106. Maula S.-M., Luukkaa M., Grenman R., Jackson D., Jalkanen S., Ristamaki R. Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region. Cancer Res. 2003, 63:1920-1926.
107. Han J., Kioi M., Chu W.S., Kasperbauer J.L., Strome S.E., Puri R.K. Identification of potential therapeutic targets in human head & neck squamous cell carcinoma. Head Neck Oncol. 2009, 1:27.
108. Lin J.-T., Chang T.-H., Chang C.-S., Wang W.-H., Su B.-W., Lee K.-D., Chang P.-J. Prognostic value of pretreatment CD44 mRNA in peripheral blood of patients with locally advanced head and neck cancer. Oral Oncol. 2010, 46:29-33.
109. Kokko L.-L., Hurme S., Maula S.-M., Alanen K., Grenman R., Kinnunen I., Ventela S. Significance of site-specific prognosis of cancer stem cell marker CD44 in head and neck squamous-cell carcinoma. Oral Oncol. 2011, 47:510-516.
110. Stoll C., Baretton G., Soost F., Terpe H.J., Domide P., Lohrs U. Prognostic importance of the expression of CD44 splice variants in oral squamous cell carcinomas. Oral Oncol. 1999, 35:484-489.
111. Carinci F., Stabellini G., Calvitti M., Pelucchi S., Targa L., Farina A., Pezzetti F., Pastore A. CD44 as prognostic factor in oral and oropharyngeal squamous cell carcinoma. J. Craniofac Surg. 2002, 13:85-89.
112. Gonzalez-Moles M.A., Gil-Montoya J.A., Ruiz-Avila I., Esteban F., Delgado-Rodriguez M., Bascones-Martinez A. Prognostic significance of p21WAF1/CIP1, p16INK4a and CD44s in tongue cancer. Oncol. Rep. 2007, 18:389-396.
113. Uwa N., Kataoka T.R., Torii I., Sato A., Nishigami T., Song M., Daimon T., Saeki N., Sagawa K., Mouri T., Terada T., Sakagami M., Tsujimura T. CD44 expression is related to poor prognosis of hypopharyngeal squamous cell carcinoma. Acta Otolaryngol. 2011, 131:323-329.
114. Magni M., Shammah S., Schiro R., Mellado W., Dalla-Favera R., Gianni A.M. Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer. Blood 1996, 87:1097-1103.
115. Douville J., Beaulieu R., Balicki D. ALDH1 as a functional marker of cancer stem and progenitor cells. Stem Cells Dev. 2009, 18:17-25.
116. Davis S.J., Divi V., Owen J.H., Bradford C.R., Carey T.E., Papagerakis S., Prince M.E. Metastatic potential of cancer stem cells in head and neck squamous cell carcinoma. Arch. Otolaryngol.-Head Neck Surg. 2010, 136:1260-1266.
117. Pannone G., Hindi S.A., Santoro A., Sanguedolce F., Rubini C., Cincione R.I., De Maria S., Tortorella S., Rocchetti R., Cagiano S., Pedicillo C., Serpico R., Lo Muzio L., Bufo P. Aurora B expression as a prognostic indicator and possible therapeutic target in oral squamous cell carcinoma. Int. J. Immunopathol. Pharmacol. 2011, 24:79-88.
118. de Maria S., Lo Muzio L., Braca A., Rega P., Cassano A., Vinella A., Fumarulo R., Serpico R., Farina E., Metafora V., Pannone G., Ravagnan G.P., Metafora S., Rubini C., Carteni M., Mariggio M.A. Survivin promoter-31 G/C polymorphism in oral cancer cell lines. Oncol. Lett. 2011, 2:935-939.
119. Papagerakis P., Pannone G., Shabana A.H., Depondt J., Santoro A., Ghirtis K., Berdal A., Papagerakis S. Aberrant beta-catenin and LEF1 expression may predict the clinical outcome for patients with oropharyngeal cancer. Int. J. Immunopathol. Pharmacol. 2012, 25:135-146.
120. Necochea-Campion R., Chen C.S., Mirshahidi S., Howard F.D., Wall N.R. Clinico-pathologic relevance of Survivin splice variant expression in cancer. Cancer Lett. 2013, 339:167-174.
121. Guindalini R.S., Mathias Machado M.C., Garicochea B. Monitoring Survivin expression in cancer: implications for prognosis and therapy. Mol. Diagn. Ther. 2013.
122. Li C., Wu J.J., Hynes M., Dosch J., Sarkar B., Welling T.H., Pasca di Magliano M., Simeone D.M. c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology 2011, 141:2218-2227. (e2215).
123. Prise K.M., Saran A. Concise review: stem cell effects in radiation risk. Stem Cells (Dayton, Ohio) 2011, 29:1315-1321.
124. Adams A., Warner K., Nor J.E. Salivary gland cancer stem cells. Oral Oncol. 2013, 49:845-853.
125. Iwatsuki M., Mimori K., Yokobori T., Ishi H., Beppu T., Nakamori S., Baba H., Mori M. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 2010, 101:293-299.
126. S. Papagerakis, G. Pannone, Epithelial-mesenchymal interactions in oral cancer metastasis. In: K.U. Ogbureke (Ed.), Oral Cancer Tech. 2012, pp. 373-388.
127. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., Brooks M., Reinhard F., Zhang C.C., Shipitsin M., Campbell L.L., Polyak K., Brisken C., Yang J., Weinberg R.A. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
128. Krishnamurthy S., Nor J.E. Head and neck cancer stem cells. J. Dent. Res. 2012, 91:334-340.
129. Biddle A., Liang X., Gammon L., Fazil B., Harper L.J., Emich H., Costea D.E., Mackenzie I.C. Cancer stem cells in squamous cell carcinoma switch between two distinct phenotypes that are preferentially migratory or proliferative. Cancer Res. 2011, 71:5317-5326.
130. Li Q., Lu L., Tao H., Xue C., Teitz-Tennenbaum S., Owen J.H., Moyer J.S., Prince M.E., Chang A.E., Wicha M.S. Generation of a novel dendritic-cell vaccine using melanoma and squamous cancer stem cells. J. Visual. Exp. 2014, 83:e50561.
131. Tsuruo T., Iida H., Nojiri M., Tsukagoshi S., Sakurai Y. Circumvention of vincristine and adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Res. 1983, 43:2905-2910.
132. Coley H.M. Overcoming multidrug resistance in cancer: clinical studies of P-glycoprotein inhibitors. Methods Mol. Biol. (Clifton, NJ) 2010, 596:341-358.
133. Zheng X., Cui D., Xu S., Brabant G., Derwahl M. Doxorubicin fails to eradicate cancer stem cells derived from anaplastic thyroid carcinoma cells: characterization of resistant cells. Int. J. Oncol. 2010, 37:307-315.
134. Ruff P., Vorobiof D.A., Jordaan J.P., Demetriou G.S., Moodley S.D., Nosworthy A.L., Werner I.D., Raats J., Burgess.L.J. A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen. Cancer Chemother. Pharmacolol. 2009, 64:763. (738).
135. Bradshaw D.M., Arceci R.J. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J. Clin. Oncol. 1998, 16:3674-3690.
136. Advani R., Lum B.L., Fisher G.A., Halsey J., Chin D.L., Jacobs C.D., Sikic B.I. A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance. Ann. Oncol. 2005 Dec, 16(12):1968-1973. (Epub 2005 Aug 26).
137. Fisher G.A., Sikic B.I. Clinical studies with modulators of multidrug resistance. Hematol. Oncol. Clin. North Am. 1995, 9:363-382.
138. Raaijmakers M.H., de Grouw E.P., van der Reijden B.A., de Witte T.J., Jansen J.H., Raymakers R.A. ABCB1 modulation does not circumvent drug extrusion from primitive leukemic progenitor cells and may preferentially target residual normal cells in acute myelogenous leukemia. Clin. Cancer Res. 2006, 12:3452-3458.
139. Zhang S., Yang X., Morris.M.E. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol. Pharmacol. 2005, 65:1208-1216.
140. Yuan J.M. Cancer prevention by green tea: evidence from epidemiologic studies. Am. J. Clin. Nutr. 2013, 98:1676S-1681S.
141. Mamaeva V., Rosenholm J.M., Bate-Eya L.T., Bergman L., Peuhu E., Duchanoy A., Fortelius L.E. Mesoporous silica nanoparticles as drug delivery systems for targeted inhibition of Notch signaling in cancer. Mol. Ther. The Journal of the American Society of Gene Therapy 2011, 19:1538-1546.
142. Mukherjee K.K., Bose A., Ghosh D., Sarkar K., Goswami S., Pal S., Biswas J., Baral.R. IFNα2b augments immune responses of cisplatin+5 fluorouracil treated tongue squamous cell carcinoma patients-a preliminary study. Indian J. Med. Res. 2012, 136:54-59.
143. Liu X., Lu J., He M.L., Li Z., Zhang B., Zhou L.H., Li Q., Li G., Wang L., Tian W.D., Peng Y., Li X.P. Antitumor effects of interferon-alpha on cell growth and metastasis in human nasopharyngeal carcinoma. Curr. Cancer Drug Targets 2012, 12:561-570.
144. Young M.R., Wright M.A., Pandit R. Myeloid differentiation treatment to diminish the presence of immune-suppressive CD34+ cells within human head and neck squamous cell carcinomas. J. Immunol. 1997, 159:990-996.
145. Ling L., Bhatia.R. Stem cell quiescence. Clin. Cancer Res. An Official Journal of the American Association for Cancer Research 2011, 17:4936-4941.
146. Lathers D.M., Lubbers E., Wright M.A., Young M.R. Dendritic cell differentiation pathways of CD34+ cells from the peripheral blood of head and neck cancer patients. J. Leukocyte Biol. 1999, 65:623-628.
147. Hoffman K.E., Pugh S.L., James J.L., Scarantino C., Movsas B., Valicenti R.K., Fortin A., Pollock J., Kim H., Brachman D.G., Berk L.B., Bruner D.W., Kachnic L.A. The impact of concurrent granulocyte-macrophage colony-stimulating factor on quality of life in head and neck cancer patients: results of the randomized, placebo-controlled radiation therapy oncology group 9901 trial. Qual. Life Res. 2014, (Feb 4).
148. Harrington K.J., Hingorani M., Tanay M.A., Hickey J., Bhide S.A., Clarke P.M., Renouf L.C., Thway K., Sibtain A., McNeish I.A., Newbold K.L., Goldsweig H., Coffin R. Nutting CM. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin. Cancer Res. 2010, 16:4005-4015.
149. Gros S.J., Kurschat N., Drenckhan A., Dohrmann T., Forberich E., Effenberger K., Reichelt U., Hoffman R.M., Pantel K., Kaifi J.T., Izbicki J.R. Involvement of CXCR4 chemokine receptor in metastastic HER2-positive esophageal cancer. PLoS One 2012, 7:e47287.
150. Uchida D., Onoue T., Kuribayashi N., Tomizuka Y., Tamatani T., Nagai H., Miyamoto Y. Blockade of CXCR4 in oral squamous cell carcinoma inhibits lymph node metastases. Eur. J. Cancer 2011, 47:452-459.
151. Stauber R.H., Knauer S.K., Habtemichael N., Bier C., Unruhe B., Weisheit S., Spange S., Nonnenmacher F., Fetz V., Ginter T., Reichardt S., Liebmann C., Schneider G., Krämer O.H. A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer. Oncotarget 2012, 3:31-43.
152. Chikamatsu K., Ishii H, Murata T, Sakakura K, Shino M, Toyoda M, Takahashi K, Masuyama K. Alteration of cancer stem cell-like phenotype by histone deacetylase inhibitors in squamous cell carcinoma of the head and neck. Cancer Sci. 2013, 104:1468-1475.
153. Conti C., Leo E., Eichler G.S., Sordet O., Martin M.M., Fan A., Aladjem M.I., Pommier Y. Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage. Cancer Res. 2010, 70:4470-4480.
154. Connolly R.M., Nguyen NK, Sukumar S. Molecular pathways: current role and future directions of the retinoic acid pathway in cancer prevention and treatment. Clin. Cancer Res. 2013, 19:1651-1659.
155. Khuri F.R., Lee J.J., Lippman S.M., Kim E.S., Cooper J.S., Benner S.E., et al. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J. Nat. Cancer Inst. 2006, 98:441-450.
156. Wei W., Chua M.-S., Grepper S., So S.K. Blockade of Wnt-1 signaling leads to anti-tumor effects in hepatocellular carcinoma cells. Mol. Cancer 2009, 8:76.
157. Gurney A., Axelrod F, Bond C.J., Cain J., Chartier C., Donigan L., Fischer M., Chaudhari A., Ji M., Kapoun A.M., Lam A., Lazetic S., Ma S., Mitra S., Park I.K., Pickell K., Sato A., Satyal S., Stroud M., Tran H., Yen W.C., Lewicki J., Hoey T. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc. Nat. Acad. Sci. U.S.A. 2012, 109:11717-11722.
158. Ettenberg S.A., Charlat O., Daley M.P., Liu S., Vincent K.J., Stuart D.D., Schuller A.G., Yuan J., Ospina B., Green J., Yu Q., Walsh R., Li S., Schmitz R., Heine H., Bilic S., Ostrom L., Mosher R., Hartlepp K.F., Zhu Z., Fawell S., Yao Y.M., Stover D., Finan P.M., Porter J.A., Sellers W.R., Klagge I.M., Cong F. Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies. Proc. Nat. Acad. Sci. U.S.A. 2010, 107:15473-15478.
159. Gong Y., Bourhis E., Chiu C., Stawicki S., DeAlmeida V.I., Liu B.Y., Phamluong K., Cao T.C., Carano R.A., Ernst J.A., Solloway M., Rubinfeld B., Hannoush R.N., Wu Y., Polakis P., Costa M. Wnt isoform-specific interactions with coreceptor specify inhibition or potentiation of signaling by LRP6 antibodies. PLoS One 2010, 5:e12682.
160. King T.D., Zhang W., Suto M.J., Li Y. Frizzled7 as an emerging target for cancer therapy. Cell Signaling 2012, 24:846-851.
161. Fernandez A., Huggins I.J., Perna L., Brafman D., Lu D., Yao S., Gaasterland T., Carson D.A., Willert.K. The WNT receptor FZD7 is required for maintenance of the pluripotent state in human embryonic stem cells. Proc. Nat. Acad. Sci. U.S.A. 2014, 111:1409-1414.
162. Ring J.E., Kolev V.N., Padval M.V., Keegan M., Vidal C.M., Neill A.A., Shapiro I.M., Pachter J.A. Xu The cancer stem cell-targeting Wnt inhibitor VS-507 reduces breast cancer growth and metastasis. Cancer Res. 2012, 72:1024.
163. Chan L.-F., Sharon R.W.-Y., Sun M.-Y., Choi Y., Zeng L., Shek S., Sin-Yin Chui C.-M.Che. An anti-cancer trinuclear ruthenium(iii) complex with 2-thiosalicylate ligands attenuates Wnt-Β-catenin signaling. Chem. Sci. 2011, 2:1788.
164. Chen H.-J, Hsu L.-S., Shia Y.-T., Lin M.-W., Lin.C.-M. The Β-catenin/TCF complex as a novel target of resveratrol in the Wnt/β-catenin signaling pathway. Biochem. Pharmacol. 2012, 84:1143-1153.
165. Tsai J.H., Hsu L.S., Lin C.L., Hong H.M., Pan M.H., Way T.D., Chen W.J. 3,5,4'-Trimethoxystilbene, a natural methoxylated analog of resveratrol, inhibits breast cancer cell invasiveness by downregulation of PI3K/Akt and Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition. Toxicol. Appl. Pharmacol. 2013, 272:746-756.
166. Chen Y.J., Chen Y.Y., Lin Y.F., Hu H.Y., Liao H.F. Resveratrol inhibits alpha-melanocyte-stimulating hormone signaling, viability, and invasiveness in melanoma cells. Evid. Based Complement. Alternat. Med. 2013, 2013:632121.
167. Shen Y.A., Lin C.H., Chi W.H., Wang C.Y., Hsieh Y.T., Wei Y.H., Chen Y.J. ResveratrolImpedes the stemness, epithelial-mesenchymal transition, and metabolic reprogramming of cancer stem cells in nasopharyngeal carcinoma through p53 activation. Evid. Based Complement. Alternat. Med. 2013, 2013:590393.
168. Pandey P.R., Xing F., Sharma S., Watabe M., Pai S.K., Iiizumi-Gairani M., Fukuda K., Hirota S., Mo Y.Y., Watabe K. Elevated lipogenesis in epithelial stem-like cell confers survival advantage in ductal carcinoma in situ of breast cancer. Oncogene 2013, 32:5111-5122.
169. Kawasaki B.T., Hurt E.M., Mistree T., Farrar W.L. Targeting cancer stem cells with phytochemicals. Mol. Interventions 2008, 8:174-184.
170. Singh S.V., Singh K. Cancer chemoprevention with dietary isothiocyanates mature for clinical translational research. Carcinogenesis 2012, 33:1833-1842.
171. Gang E.J., Hsieh Y.T., Pham J., Zhao Y., Nguyen C., Huantes S., Park E., Naing K., Klemm L., Swaminathan S., Conway E.M., Pelus L.M., Crispino J., Mullighan C.G., McMillan M., Müschen M., Kahn M., Kim Y.M. Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia. Oncogene 2013.
172. Wend P., Fang L., Zhu Q., Schipper J.H., Loddenkemper C., Kosel F., Brinkmann V., Eckert K., Hindersin S., Holland J.D., Lehr S., Kahn M., Ziebold U., Birchmeier W. Wnt/β-catenin signalling induces MLL to create epigenetic changes in salivary gland tumours. EMBO J. 2013, 32:1977-1989.
173. Hallett R.M., Kondratyev M.K., Giacomelli A.O., Nixon A.M., Girgis-Gabardo A., Ilieva D., Hassell J.A. Small molecule antagonists of the Wnt/β-catenin signaling pathway target breast tumor-initiating cells in a Her2/Neu mouse model of breast cancer. PLoS One 2012, 7:e33976.
174. Chen B., Dodge M.E., Tang W., Lu J., Ma Z., Fan C.-W., Wei S. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat. Chem. Biol. 2009, 5:100-107.
175. Jiang X., Hao H.-X., Growney J.D., Woolfenden S., Bottiglio C., Ng N., Lu B. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proc. Nat. Acad. Sci. U.S.A. 2013, 110:12649-12654.
176. Proffitt K.D., Madan B., Ke Z., Pendharkar V., Ding L., Lee M.A., Hannoush R.N., Virshup D.M. Pharmacological inhibition of the Wnt acyltransferase PORCN prevents growth of WNT-driven mammary cancer. Cancer Res. 2013, 73:502-507.
177. Liu J., Pan S., Hsieh M.H., Ng N., Sun F., Wang T., Kasibhatla S., Schuller A.G., Li A.G., Cheng D., Li J., Tompkins C., Pferdekamper A., Steffy A., Cheng J., Kowal C., Phung V., Guo G., Wang Y., Graham M.P., Flynn S., Brenner J.C., Li C., Villarroel M.C., Schultz P.G., Wu X., McNamara P., Sellers W.R., Petruzzelli L., Boral A.L., Seidel H.M., McLaughlin M.E., Che J, Carey T.E., Vanasse G., Harris JL. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc. Nat. Acad. Sci. U.S.A. 2013, 110:20224-20229.
178. Huang Y.C., Chao K.S., Liao HF, Chen Y.J. Targeting sonic hedgehog signaling by compounds and derivatives from natural products. Evid. Based Complement. Alternat. Med. 2013, 2013:748587.
179. Keysar S.B., Le P.N., Anderson R.T., Morton J.J., Bowles D.W., Paylor J.J., Vogler B.W. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer. Cancer Res. 2013, 73:3381-3392.
180. Olsauskas-Kuprys R., Zlobin A., Osipo C. Gamma secretase inhibitors of Notch signaling. OncoTargets Ther. 2013, 6:943-955.
181. Yoshida R., Nagata M., Nakayama H., Niimori-Kita K., Hassan W., Tanaka T., Shinohara M., Ito T. The pathological significance of Notch1 in oral squamous cellcarcinoma. Lab. Invest. 2013, 93:1068-1081.
182. Chen S.M., Liu J.P., Zhou J.X., Chen C., Deng Y.Q., Wang Y., Tao Z.Z. Suppression of the notch signaling pathway by γ-secretase inhibitor GSI inhibits human nasopharyngeal carcinoma cell proliferation. Cancer Lett. 2011, 306:76-84.
183. Yu S., Zhang R., Liu F., Hu H., Yu S., Wang H. Down-regulation of Notch signalingby a γ-secretase inhibitor enhances the radiosensitivity of nasopharyngeal carcinoma cells. Oncol. Rep. 2011, 26:1323-1328.
184. Subramaniam D., Ponnurangam S., Ramamoorthy P., Standing D., Battafarano R.J., Anant S., Sharma P. Curcumin induces cell death in esophageal cancer cells through modulating Notch signaling. PLoS One 2012, 7:e30590.
185. Cecchinato V., Chiaramonte R., Nizzardo M., Cristofaro B., Basile A., Sherbet G.V., Comi P. Resveratrol-induced apoptosis in human T-cell acute lymphoblastic leukaemia MOLT-4 cells. Biochem. Pharmacol. 2007, 74:1568-1574.
186. Suman S., Das TP, Damodaran C. Silencing NOTCH signaling causes growth arrest in both breast cancer stem cells and breast cancer cells. Br. J. Cancer 2013, 109:2587-2596.
187. Koppaka V., Thompson D.C., Chen Y., Ellermann M., Nicolaou K.C., Juvonen R.O., Petersen D., Deitrich R.A., Hurley T.D., Vasiliou V. Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application. Pharmacol. Rev. 2012, 64:520-539.
188. + human breast cancer cells. Breast Cancer Res. Treat. 2012, 133:75-87.
189. Liu P., Kumar I.S., Brown S., Kannappan V., Tawari P.E., Tang J.Z., Jiang W., Armesilla A.L., Darling J.L., Wang W. Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells. Br. J. Cancer 2013, 109:1876-1885.
190. Januchowski R., Wojtowicz K., Zabel M. The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance. Biomed. Pharmacother. 2013, 67:669-680.
191. Landen C.N., Goodman B., Katre A.A., Steg A.D., Nick A.M., Stone R.L., Miller.L.D. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol. Cancer Ther. 2010, 9:3186-3199.
192. Azmi A.S., Bollig-Fischer A., Bao B., Park B.-J., Lee S.-H., Yong-Song G., Dyson G., Reddy C., Sarkar F.H., Mohammad R.M. Systems analysis reveals a transcriptional reversal of the mesenchymal phenotype induced by SNAIL-inhibitor GN-25. BMC. Syst. Biol. 2013, 7:85.
193. Glick A.B. The role of TGFβ signaling in squamous cell cancer: lessons from mouse models. J. Skin Cancer 2012, 249063.
194. Lee T.K., Poon R.T.P., Wo J.Y., Ma S., Guan X.-Y., Myers J.N., Altevogt P., Yuen.A.P.W. Lupeol suppresses cisplatin-induced nuclear factor-kappaB activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model. Cancer Res. 2007, 67:8800-8809.
195. Prasad S., Ravindran J., Aggarwal.B.B. NF-kappaB and cancer: how intimate is this relationship. Mol. Cell. Biochem. 2010, 336:25-37.
196. Lo W.-L., Yu Cheng-Chia, Chiou Guang-Yuh, Chen Yi-Wei, Huang Pin-I, Chien Chian-Shiu, Tseng Ling-Ming, et al. MicroRNA-200c attenuates tumour growth and metastasis of presumptive head and neck squamous cell carcinoma stem cells. J. Pathol. 2011, 223:482-495.
197. Saini S., Arora Sumit, Majid Shahana, Shahryari Varahram, Chen Yi, Deng Guoren, Yamamura Soichiro, Ueno Koji, Dahiya Rajvir Curcumin modulates microRNA-203-mediated regulation of the Src-Akt axis in bladder cancer. Cancer Prev. Res. (Philadelphia, PA) 2011, 4:1698-1709.
198. Merlano M., Occelli M. Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck. Ther. Clin. Risk Manage. 2007, 3:871-876.
199. Lee N.Y., Zhang Qiang, Pfister David G., Kim John, Garden Adam S., Mechalakos James, Hu Kenneth, et al. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncol. 2012, 13:172-180.
200. Cohen E., Davis Darren W., Karrison Theodore G., Seiwert Tanguy Y., Wong Stuart J., Nattam Sreenivasa, Kozloff Mark F., et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol. 2009, 10:247-257.
201. Del Campo J.M., Hitt R., Sebastian P., Carracedo C., Lokanatha D., Bourhis J., Temam S., et al. Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck. Br. J. Cancer 2011, 105:618-627.
202. Kutluk Cenik B., Ostapoff Katherine T., Gerber David E., Brekken Rolf A. BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer. Mol. Cancer Ther. 2013, 12:992-1001.
203. Williamson S.K., Moon James, Huang Chao H., Guaglianone Perry P., LeBlanc Michael, Wolf Gregory T., Urba Susan G. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. J. Clin. Oncol. Official Journal of the American Society of Clinical Oncology 2010, 28:3330-3335.
204. Gilmartin A.G., Bleam Maureen R., Groy Arthur, Moss Katherine G., Minthorn Elisabeth A., Kulkarni Swarupa G., Rominger Cynthia M., et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin. Cancer Res. An Official Journal of the American Association for Cancer Research 2011, 17:989-1000.
205. Argiris A., Cohen Ezra, Karrison Theodore, Esparaz Benjamin, Mauer Ann, Ansari Rafat, Wong Stuart, et al. A Phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol. Ther. 2006, 5:766-770.
206. Garlich J.R., De Pradip, Dey Nandini, Dong Su Jing, Peng Xiaodong, Miller Antoinette, Murali Ravoori, et al. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res. 2008, 68:206-215.
207. Freudlsperger C., Burnett Jeffrey R., Friedman Jay A., Kannabiran Vishnu R., Chen Zhong, Van Waes Carter EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy. Expert Opin. Ther. Targets 2011, 15:63-74.
208. Cai Z., Ke J., He X., Yuan R., Chen Y., Wu X., Wang L., Wang J., Lan P., Wu X. Significance of mTOR signaling and its inhibitor against cancer stem-like cells in colorectal cancer. Ann. Surg. Oncol. 2014, 21:179-188.
209. Zaytseva Y.Y., Valentino Joseph D., Gulhati Pat, Mark Evers B mTOR inhibitors in cancer therapy. Cancer Lett. 2012, 319:1-7.
210. Erlich R.B., Kherrouche Z., Rickwood D., Endo-Munoz L., Cameron S., Dahler A., Hazar-Rethinam M., de Long L.M., Wooley K., Guminski A., Saunders N.A. Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma. Br. J. Cancer 2012, 106:107-115.
211. Roulin D., Waselle Laurent, Dormond-Meuwly Anne, Dufour Marc, Demartines Nicolas, Dormond Olivier Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib. Mol. Cancer 2011, 10:90.
212. D'Ascenzo M., Piacentini R., Casalbore P., Budoni M., Pallini R., Azzena G.B., Grassi C. Role of L-type Ca2+ channels in neural stem/progenitor cell differentiation. Eur. J. Neurosci. 2006, 23:935-944.
213. Zhang Y., Crump M., Berge S.A. Purging of contaminating breast cancer cells from hematopoietic progenitor cell preparations using activation enhanced cell death. Breast Cancer Res. Treat. 2002, 72:265-278.
214. Wu Y., Palad A.J., Wasilenko W.J., Blackmore P.F., Pincus W.A., Schechter G.L., Spoonster J.R., Kohn E.C., Somers K.D. Inhibition of head and neck squamous cell carcinoma growth and invasion by the calcium influx inhibitor carboxyamido-triazole. Clin. Cancer Res. 1997, 3:1915-1921.
215. Cioce M., Gherardi S., Viglietto G., Strano S., Blandino G., Muti P., et al. Mammosphere-forming cells from breast cancer cell lines as a tool for the identification of CSC-like- and early progenitor-targeting drugs. Cell Cycle 2010, 9:2878-2887.
216. Chiou S.H., Yu C.C., Huang C.Y., Lin S.C., Liu C.J., Tsai T.H., Chou S.H., Chien C.S., Ku H.H., Lo J.F. Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin. Cancer Res. 2008, 14:4085-4095.
217. Tabor M.H., Clay M.R., Owen J.H., Bradford C.R., Carey T.E., Wolf G.T., Prince M.E. Head and neck cancer stem cells: the side population. Laryngoscope 2011, 12:527-533.
218. Chen H., Zhou L., Dou T., Wan G., Tang H., Tian J. Bmi-1's maintenance of the proliferative capacity of laryngeal cancer stem cells. Head Neck 2011, 33:1115-1125.
219. Huang C.F., Xu X.-R., Wu T.-F., Sun Z.-J., Zhang W.F. Correlation of ALDH1, CD44, OCT4 and SOX2 in tongue squamous cell carcinoma and their association with disease progression and prognosis. J. Oral Pathol. Med. 2014.
220. Laimer K., Fong D., Gasti G., Obrist P., Kloss F., Tuli T., Spizzo G. EpCam expression in squamous cell carcinoma of the oral cavity: frequency and relationship to clinicopathologic features. Oral Oncol. 2008, 44:72-77.
221. Qiao B., He B., Cai J., Yang W. The xpresion profile of Oct4 and Sox 2 in the carcinogenesis of oral mucosa. Int. J. Clin. Exp. Pathol. 2014, 7:28-37.
222. Han J., Fujisawa T., Husain S.R., Puri R.K. Identification and characterization of cancer stem cells in human head and neck squamous cell carcinoma. BioMed. Central Cancer 2014, 11:1471-2407.
223. Marynka-kalmani K., treves S., Yafee M., Rachima H., Gafni Y., Cohen M.A., et al. The lamina propria of adult human oral mucosa harbors a novel stem cell population. Stem Cell 2010, 28:984-995.
224. Sheu L.-F., Lee W.-C., Lee H.-S., Kao W.-Y., Chen A. Co-expression of c-kit and stem cell factor in primary and metastatic nasopharyngeal carcinomas and nasopharyngeal epithelium. J. Pathol. 2005, 207:216-223.
225. Biddle A., Liang X., Gammon L., Fazil B., Harper L.J., Emich H., Costea D.E., Mackenzie I.C. Cancer stem cells in squamous carcinoma switch between two distinct phenotypes that are preferentially migratory or proliferative. Cancer Res. 2011, 71:5317-5326.